Excitement is palpable among Harry Perkins Institute researchers as they progress the approval stages of a drug that may have the damaging peripheral artery disease on the run.
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.